Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane is a synthetic small molecule compound with the molecular formula C18H38N4S2 and a molecular weight of approximately 374.7 g/mol. It belongs to the class of isothiourea derivatives and has been studied as an inhibitor of nitric oxide synthase (NOS), particularly targeting the heme domain of endothelial NOS. Structural studies have shown that bulky bis(isothiourea)s like this compound can bind to the active site pocket of NOS enzymes, providing insights for isoform-selective inhibitor design. Its primary mechanism involves inhibition of nitric oxide synthase activity, which may be relevant in modulating physiological and pathological NO production[7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane.